SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-161685
Filing Date
2024-06-14
Accepted
2024-06-14 16:41:58
Documents
14
Period of Report
2024-06-13
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d853541d8k.htm   iXBRL 8-K 33366
  Complete submission text file 0001193125-24-161685.txt   192028

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tpst-20240613.xsd EX-101.SCH 3884
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tpst-20240613_def.xml EX-101.DEF 13699
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tpst-20240613_lab.xml EX-101.LAB 22683
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tpst-20240613_pre.xml EX-101.PRE 14667
18 EXTRACTED XBRL INSTANCE DOCUMENT d853541d8k_htm.xml XML 5520
Mailing Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005 415-798-8589
Tempest Therapeutics, Inc. (Filer) CIK: 0001544227 (see all company filings)

IRS No.: 451472564 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35890 | Film No.: 241045509
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)